Johns Hopkins scientists zero in on how cancers resist immun
Results of an initial study of tumors from patients with certain cancers shed light on the widespread acquired resistance to immunotherapy drugs known as checkpoint inhibitors.

The study, conducted by researchers on five patients at the Johns Hopkins Kimmel Cancer Center, suggests the resistance is due to the elimination of certain genetic mutations that enable the immune system to recognize and attack malignant cells. The results of their researcher is described online in Cancer Discovery....